Starpharma

Biotechnology ResearchVictoria, Australia51-200 Employees

Starpharma Holdings Limited is an Australian biotechnology company focused on developing pharmaceutical and medical products based on dendrimer-based polymers. Headquartered in Abbotsford, Victoria, it operates globally within the biopharmaceutical sector. Its programs span therapies targeting respiratory viruses, a nanoparticle drug-delivery platform known as DEP, and the VivaGel product line. A 2021 patent grant from the US Patent and Trademark Office covers DEP cabazitaxel, a nanoparticle formulation linked to prostate cancer treatment.

The company pursues partnerships with other industry players, including Merck & Co. (MSD), to advance DEP-based research, such as a preclinical evaluation of a DEP antibody-drug conjugate. In its positioning, Starpharma operates within the biotechnology research field, delivering antiviral and drug-delivery programs to medical and research customers.

Sign up for free to view info

Email Format Employee directory